The DOI matches its Crossref record.
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study
Open accessAbstract
OBJECTIVE: To study the effect of entacapone, a specific peripherally acting catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa treatment, in cases of Parkinson's disease with both fluctuating and non-fluctuating response to treatment. METHODS: A randomised, placebo controlled, double blind, six month study was undertaken in 172 fluctuating and 128 non-fluctuating patients. The clinical efficacy and safety of 200 mg entacapone given with each daily levodopa dose was studied. Efficacy was examined using home diaries, the unified Parkinson disease rating scale (UPDRS), and recording of daily levodopa dose. RESULTS: The primary efficacy variable for fluctuating patients-the proportion of daily ON time-showed a significant increase compared with placebo (p < 0.05). The absolute ON time (mean (SD)) increased from 9.5 (2.5) to 10.8 (2.4) hours (p < 0.01), and the daily OFF time was correspondingly reduced from 7.0 (2.6) to 5.9 (2.5) hours (p < 0.05 v placebo). This improvement was achieved despite a reduction in daily levodopa requirements. The effect was rapidly lost on withdrawal of entacapone. In non-fluctuating patients, the primary efficacy measure was part II of the UPDRS (activities of daily living; ADL). In this group of patients, ADL scores improved in the entacapone group (p < 0.01 v placebo), and there was also a 40 mg reduction in levodopa requirement (p < 0.01 v placebo). Entacapone was well tolerated by both fluctuating and non-fluctuating patients. CONCLUSIONS: The ability of entacapone to provide additional benefits to levodopa treatment in increasing ON time in fluctuating Parkinson's disease patients was confirmed. A novel finding was that patients without fluctuations also obtained benefit from the addition of entacapone to their levodopa treatment, as evidenced by improved ADL scores and a relatively reduced levodopa requirement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Nepali, K., Lee, H.-Y., & Liou, J.-P. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00147 · Cited by 629
Goetz, C. G., Poewe, W., Rascol, O., & Sampaio, C. (2005) · Movement Disorders · doi:10.1002/mds.20464 · Cited by 376
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Novel pharmacological targets for the treatment of Parkinson's disease
Schapira, A. H. V., Bezard, E., Brotchie, J., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, E., Jenner, P., Novère, N. L., et al. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2087 · Cited by 298
Minimal clinically important change on the unified Parkinson's disease rating scale
Schrag, A., Sampaio, C., Counsell, N., & Poewe, W. (2006) · Movement Disorders · doi:10.1002/mds.20914 · Cited by 297
Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies
Thanvi, B. R., & Lo, T. C. N. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2003.013912 · Cited by 194
Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
Müller, T. (2015) · Drugs · doi:10.1007/s40265-014-0343-0 · Cited by 190
Stacy, M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0424-5 · Cited by 66
“…pharmacokinetic profile in patients with wearing-off include reduction in OFF-time, improvement in motor function, activities of daily living, and quality of life (QoL) (Brooks and Sagar 2003; Poewe et al. 2002; Rinne et al. 1998; Durif et al. 2001; Fenelon et al. 2003; Parkinson Study Group 1997).”
Background
Metadata
- Authors
- Brooks, D. J.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2003-08-01
- Volume
- 74
- Issue
- 8
- Pages
- 1071-1079
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2170999819
- Cited by
- 182
- References
- 0
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.